About Lynne Rollins
Form D filings for Transposon Therapeutics from 2020 to 2024 list Lynne Rollins as executive officer.
Form D filings also name Lynne Rollins as an executive officer at Abrexa Pharmaceuticals.
Lynne Rollins first appears on SEC filings in 2011.
Experience
This experience comes from SEC filings. The years are when the filings name Lynne Rollins in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Lynne Rollins works with at each company, as listed on that company's latest Form D.
Transposon Therapeutics, Inc. · Form D, Jul 15, 2024
KK
Keith Katkin
Director
DP
Dennis Podlesak
Chief Executive Officer and director
DM
Daniel Hetu, MD, MBA
Director
EM
Eckard Weber, MD
Executive officer and director
BA
Brent Ahrens
Director
BM
Brian Slingsby, MD, PHD, MPH
Director
WM
William Harrington, MD, MBA
Director
JP
John Pacifico
Director
Abrexa Pharmaceuticals, Inc. · Form D, Sep 6, 2011
ED
Eckard Weber, M.D.
President and Chief Executive Officer, director
NV
Nicole Vitullo
Director